Novavax (NVAX) Gains from Sales and Divestitures (2019 - 2020)
Novavax (NVAX) recorded quarterly Gains from Sales and Divestitures of $781812.0 in Q3 2020, up 1543.74% quarter-over-quarter from $47563.0 in Q2 2020, and up 976.33% on a YoY basis from $72637.0 in Q4 2019.
Novavax (NVAX) Gains from Sales and Divestitures (2019 - 2020) Analysis & Trends
Novavax's Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $781812.0 for Q3 2020.
- In Q3 2020, Gains from Sales and Divestitures rose 976.33% year-over-year to $781812.0; the TTM figure through Sep 2020 stood at $781812.0 (up 976.33% YoY), while the FY2019 annual figure was $72637.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $781812.0 for Q3 2020 at Novavax, up from $47563.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $781812.0 in Q3 2020 to a low of $17563.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 781,812.00 |
| Sep 30, 2020 | 781,812.00 |
| Jun 30, 2020 | 47,563.00 |
| Jun 30, 2020 | 47,563.00 |
| Mar 31, 2020 | 17,563.00 |
| Mar 31, 2020 | 17,563.00 |
| Dec 31, 2019 | 72,637.00 |
| Dec 31, 2019 | 72,637.00 |
| Sep 30, 2019 | 72,637.00 |
| Sep 30, 2019 | 72,637.00 |